NCT04275713 (METOXY-LACC) is a Phase 2 clinical trial of Metformin in Cervical Cancer, sponsored by Oslo University Hospital.

Who is sponsoring NCT04275713?

NCT04275713 is sponsored by Oslo University Hospital.

What drugs are being tested in NCT04275713?

Interventions in NCT04275713: Metformin, Cisplatin.

What condition does NCT04275713 study?

NCT04275713 studies Cervical Cancer.

Is NCT04275713 still recruiting?

NCT04275713 is currently completed. Last updated 20 January 2025.

Last reviewed 2025-01-20 · How we verify

NCT04275713: METOXY-LACC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC

Completed Phase 2 Last updated 20 January 2025

What this trial tests

Phase 2 trial testing Metformin in Cervical Cancer in 41 participants. Completed in 8 November 2024.

Timeline

22 May 2020

Primary endpoint
11 June 2024

8 November 2024

Quick facts

Lead sponsor	Oslo University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	22 May 2020
Primary completion	11 June 2024
Estimated completion	8 November 2024
Sites	1 location across Norway

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Oslo University Hospital

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Poor tumor oxygenation (hypoxia) is an established negative prognostic and predictive factor in locally advanced cervical cancer (LACC). Hypoxia-modifying measures implemented in the clinic are lacking. Metformin is a well-known, well-tolerated and low-cost drug used for decades in the treatment of type 2- diabetes. Recent studies suggest an improved tumor oxygenation by metformin potentially improving radiotherapy response and patient outcome. This study is a randomized, phase II, open label study in patients with LACC where patients are randomized to standard cisplatin-based chemoradiotherapy +/- Metformin. Metformin will be started one week prior to the start of chemoradiotherapy, and will be continued throughout the entire radiation treatment. Tumor oxygenation will be evaluated by gene signatures and MRI- parameters.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, et al · · 2020 · cited 135× · PMID 33552076 · DOI 10.3389/fimmu.2020.613114
Tumor hypoxia: From basic knowledge to therapeutic implications.
Liao C, Liu X, Zhang C, Zhang Q. · · 2023 · cited 123× · PMID 36603793 · DOI 10.1016/j.semcancer.2022.12.011
Interfering with Tumor Hypoxia for Radiotherapy Optimization.
Telarovic I, Wenger RH, Pruschy M. · · 2021 · cited 119× · PMID 34154610 · DOI 10.1186/s13046-021-02000-x
Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism.
Hamanaka RB, Mutlu GM. · · 2021 · cited 69× · PMID 33393204 · DOI 10.1111/febs.15693
Perspectives on Hypoxia Signaling in Tumor Stroma.
Zhang Y, Coleman M, Brekken RA. · · 2021 · cited 28× · PMID 34202979 · DOI 10.3390/cancers13123070
Molecular and Cellular Mechanisms of Metformin in Cervical Cancer.
Chen YH, Wang PH, Chen PN, Yang SF, et al · · 2021 · cited 26× · PMID 34067321 · DOI 10.3390/cancers13112545
Mitochondrial Metabolism: A New Dimension of Personalized Oncology.
Behnam B, Taghizadeh-Hesary F. · · 2023 · cited 25× · PMID 37627086 · DOI 10.3390/cancers15164058
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity.
Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, et al · · 2020 · cited 22× · PMID 32580139 · DOI 10.1016/j.ebiom.2020.102841

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Oslo University Hospital trials

Trials by the same sponsor.

NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04275713 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
Last refreshed: 20 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04275713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing